Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.69 |
| ▸ | ADA | P00813 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2'-B-Methyl-Guanosine SCHEMBL11888942 | 1.00 | ADORA2A (0.69) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL10316549 | 1.00 | ADORA2A (0.69) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL10137892 | 0.90 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL14589609 | 0.90 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL873738 | 0.90 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL474849 | 0.90 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL10169502 | 0.90 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL15908433 | 0.90 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL1552038 | 0.88 | ADORA2A (0.53) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL1552034 | 0.88 | ADORA2A (0.53) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476169-A4 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO INC (US) | 2009-06-03 | — | — | EP | claimed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| EP-1476169-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | Merck & Co., Inc. (US) | 2004-11-17 | — | — | EP | claimed |
| WO-2003068244-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO., INC. (US) | 2003-08-21 | — | — | WO | claimed |
| EP-2937350-B9 | 1' -substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES INC (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-2697241-B1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3150608-B1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| EP-2937350-B1 | 1' -substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES INC (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-3219713-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2523950-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-2132216-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | Novartis Pharma AG. (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009132123-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132135-A1 | 1' -SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2008095993-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | ADORA2A 93/4885ADA 31/4885ADORA3 139/4885 |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | CDA, PNP, MTAP | ADORA2A 41/4885ADA 6/4885ADORA3 50/4885 |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | ITPA, PNP, NUDT1 | ADORA2A 192/4885ADA 43/4885ADORA3 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.